Article Per Year (5 Year)
p-Index From 2021 - 2026
0.659
P-Index
This Author published in this journals
All Journal Humaniora: Journal of Linguistics, Literature, and Education International Journal of Health and Pharmaceutical (IJHP)
Warham, Warham
Unknown Affiliation
Languange, Linguistic, Communication & Media Nursing Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Narcissistic Personality Disorder In The Novel Best Day Ever By Kaira Rouda Warham, Warham; Moelier , Dahlia D.; Abeng, Andi Tenri
Humaniora: Journal of Linguistics, Literature, and Education Vol. 4 No. 1 (2024): HUMANIORA: Journal of Linguistics, Literature and Education, Juni 2024
Publisher : Fakultas Sastra, Universitas Bosowa

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56326/jlle.v4i1.4901

Abstract

This study aimed to identify the causes and types of narcissistic personality disorder in the main character of Kaira Rouda's novel, "Best Day Ever" and hoped to provide a foundation for further research in this area. The data source for this study was the novel itself. Qualitative descriptive research methods were used to analyse the data with a psychological approach, including the techniques of reading, note-taking, and analysis. Caligor et al’s and Bursten's theories were used to classify the data. The results of this study reveal that the main character was a narcissist. he had 8 out of 9 signs of narcissistic personality disorder caused by excessive self-importance, fantasies of success, feelings of being special, excessive need for admiration, arrogance, and lack of empathy, and the main character's narcissistic personality disorder was predominantly of the manipulative type
Febuxostat In Hyperuricemic Heart Failure: A Systematic Review of Cardiovascular Outcomes and Safety Warham, Warham; Octavien Wijaya, Jonea; Valerian Soumokil, Willy; Islamy, Nur; Afiah Sudarianto, Nurul
International Journal of Health and Pharmaceutical (IJHP) Vol. 5 No. 4 (2025): November 2025 ( Indonesia - Thailand)
Publisher : CV. Inara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51601/ijhp.v5i4.469

Abstract

Introduction: Hyperuricemia is highly prevalent in patients with heart failure (HF) and is associated with poor prognosis. Febuxostat, a selective non-purine xanthine oxidase inhibitor, provides potent urate-lowering effects and may reduce oxidative stress, but its cardiovascular safety in HF populations remains uncertain. Objective: To systematically review the evidence on febuxostat use in patients with hyperuricemia and heart failure, focusing on cardiovascular outcomes, safety, and mechanistic effects. Methods: This review was conducted according to PRISMA guidelines. Comprehensive searches of PubMed, Cochrane Library, and ScienceDirect up to September 2025 identified studies evaluating febuxostat in hyperuricemic HF patients. Eligible designs included randomized controlled trials, post hoc analyses, and observational cohorts. Data were extracted on study characteristics, interventions, comparators, outcomes, and risk of bias. Results: From 247 records screened, eight studies were included in the qualitative synthesis. Febuxostat consistently reduced serum uric acid levels and improved oxidative stress markers and diastolic function indices. Clinical outcome data were heterogeneous: while one large trial reported increased cardiovascular mortality, another demonstrated non-inferiority without excess risk. Subgroup and observational data suggested that HFpEF patients may benefit from febuxostat in terms of reduced hospitalization and mortality, whereas evidence in HFrEF was inconclusive. Risk of bias was generally low in randomized trials but higher in observational studies. Discussion: The findings highlight febuxostat’s mechanistic plausibility and potential phenotype-specific benefits, particularly in HFpEF. However, conflicting mortality signals from pivotal trials necessitate cautious interpretation. Limitations include small sample sizes in HF-focused studies, heterogeneity in patient populations, and limited long-term outcome data. Conclusion: Febuxostat is a potent urate-lowering therapy with mechanistic benefits in hyperuricemic HF, but evidence on clinical outcomes remains inconsistent. Selective use in carefully chosen HFpEF patients may be considered, pending further large randomized trials to clarify safety and efficacy.
Effects of Inclisiran on Systemic Inflammatory Biomarkers: A Systematic Review Warham, Warham; Fitriani Andi Padri, Nurul; Zeth, Wiking; Istiqamah Ahmad, Annisa; Miftahulresty Aksi, Asdwiyenti; Asshiddiq Suhardi Andi Ara, Azhim
International Journal of Health and Pharmaceutical (IJHP) Vol. 6 No. 1 (2026): February 2026
Publisher : CV. Inara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51601/ijhp.v6i1.515

Abstract

Background: Inclisiran is a novel small interfering RNA (siRNA) therapy that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby introducing an innovative method for the regulation of lipid levels. The implications of this intervention regarding systemic inflammatory biomarkers necessitate comprehensive investigation. Objective: To thoroughly evaluate how inclisiran influences inflammatory markers, especially high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), among a group of people identified with hypercholesterolemia or atherosclerotic cardiovascular disease. Methods: A thorough systematic literature review was performed in accordance with the PRISMA 2020 guidelines. A meticulous search was undertaken across three databases (Scopus, ScienceDirect, PubMed) encompassing the timeframe from January 2017 to December 2025. Two independent reviewers engaged in the processes of filtering, extracting information, and quality evaluation by using the Cochrane RoB 2.0 tool, specifically crafted for randomized controlled trials (RCTs). Results: Out of an initial cohort of 304 records, 11 studies met the predetermined inclusion criteria, encompassing 4 noteworthy phase 2-3 randomized controlled trials (RCTs) (ORION-1, -9, -10, -11). Inclisiran revealed considerable reductions in LDL-C concentrations (varying from 47.9% to 52.6%), while demonstrating neutral effects on hs-CRP levels, which encompassed non-significant increases when compared to placebo (for example, from 3.5% to 8.5%). No investigations have provided data pertaining to IL-6 or TNF-α. All RCTs evaluated demonstrated a significantly low propensity for bias. Conclusions: Current empirical research indicates that inclisiran does not significantly influence systemic hs-CRP levels and lacks comprehensive data regarding other essential inflammatory biomarkers. The enhancements noted in cardiovascular wellness tied to this medication seem to be chiefly dictated by major declines in LDL-C concentrations, instead of variations in overall inflammation. Upcoming research on heart health results must incorporate a wide selection of inflammatory indicators to fully explain the complicated impacts of inclisiran.
Co-Authors Abeng, Andi Tenri Afiah Sudarianto, Nurul Asshiddiq Suhardi Andi Ara, Azhim Fitriani Andi Padri, Nurul Islamy, Nur Istiqamah Ahmad, Annisa Miftahulresty Aksi, Asdwiyenti Moelier , Dahlia D. Octavien Wijaya, Jonea Valerian Soumokil, Willy Zeth, Wiking